cardiology 🫀 fellow @SIUHOSPITAL " Audemars that’s losing time ". MD👨🏾‍⚕️// internal medicine certified . Formula 1 🏎 enthusiast.

Manhattan, NY
Joined June 2010
Chris Agyingi, MD retweeted
For clarification purposes, Lewis wasn’t called to pit under VSC on lap 39. Leclerc was. Shortly after the VSC Hamilton was reminded he was on Plan B and they were getting close to his pit stop. That was when he made the call to stay out in the hopes that another VSC would be deployed. I believe that’s the call he is apologising for. #F1 #SingaporeGP
151
834
165
5,480
240,076
Chris Agyingi, MD retweeted
We don't ask whether a model touched their prose. We ask authors to own every word. @JACCJournals parted w/ICMJE & doesn't require disclosure of AI writing help: the rule is unenforceable, biased, & not good for medical communication. My Editor's Page: jacc.org/doi/10.1016/j.jacc.…
15
64
27
224
37,047
Chris Agyingi, MD retweeted
I built an interactive echocardiography tutorial with Claude Code. Chapter 07: a 3D heart, the standard imaging views, the probe position, and simulated ultrasound video.
60
262
14
1,545
107,633
Chris Agyingi, MD retweeted
This is my 10 point conversations, I tend to have with any patient who might have had a predetermined mindset based on social media, CHATGPT or influencers. 1. Based on your age/gender and risk, you are already a candidate for statins, if you choose CAC, there is a 40-50% chance that you may have #PowerOfZero and likely risk below threshold of why suggested statins, allowing you flexible decisions. jacc.org/doi/10.1016/j.jacc.… 2. There is no other good tests that will give you the same information about derisking to guide you optimal information to derisk ahajournals.org/doi/full/10.… 3. If decide to make decisions based on CAC vs current risk scores, likely will result in better adherence as seen in the yet to be published CorCal, CAUGHT CAD RCT’s as well accumulation of retrospective literature sciencedirect.com/science/ar… jamanetwork.com/journals/jam… 4. Likely better LDL and risk factors control (EISNER and Caught CAD) jacc.org/doi/10.1016/j.jacc.… jamanetwork.com/journals/jam… 5. In a shorter term, CAC guided decisions will likely reduce the risk of plaque progression based on CAUGHT CAD jamanetwork.com/journals/jam… 6. Thankfully if we can keep the price $150 or less or impact your disutility of taking pills it is even cost effective from a societal perspective jacc.org/doi/10.1016/j.jcmg.… 7. In a clinical trial those randomized to decision based on CAC vs not CAC, we haven’t seen increased risk of extra stress tests, caths or stenting/bypass (EISNER) jacc.org/doi/10.1016/j.jacc.… 8. While to date there is no data showing CAC guided decision will reduce the risk of CVD clinical events in a short term period, the studies have shown a) there is no increased risk (harm) of MACE (CorCal), b) prior non randomized studies have suggested no better outcomes with statin use, suggesting no harm if you decide to have flexible goals jacc.org/doi/10.1016/j.jcmg.… 9. CAC is not one time test, if zero and don't go on treatment repeat in 3-7 yrs based on baseline risk estimate to guide if need to change the decision course jacc.org/doi/10.1016/j.jcmg.… 10. Now based on studies, CAC beyond guiding you whether you need statin or not, can help as a dosing strategy (higher risk, higher intensity) now acknowledged also by cholesterol management guidelines pmc.ncbi.nlm.nih.gov/article… Once we have provided all the information, let patient make the decisions (see our approach below below) bmj.com/content/373/bmj.n776… @rblument1 @MichaelJBlaha @DrMichaelShapir @DrMarthaGulati @AlexRazavi @Sadeer_AlKindi @miguelcainzos23 @HMHCardioFellow @CiccaroneCenter @ASPCardio @JamalRanaMD
Khurram, respectfully, your reply perfectly captures the issues I have with this test. FROM THE PATIENTS POINT OF VIEW, they do not have coronary disease prior to the CAC. After the test, they have that diagnosis which they will Google and ask ChatGPT about. This will trigger a range of downstream actions ranging from taking a statin (good) to anxiety (bad) or unneccessary testing (very bad). So in my view, which matches the patient perpective, this is indeed a screening test. You may see it as a decision tool, but the patient and those outside medicine see it as a diagnostic/screening test for sure.
2
21
6
53
20,329
Chris Agyingi, MD retweeted
Replying to @BSCMR
@BSCMR @BSHeartFailure @BHRSociety @BritishCardioSo endorsement of the BRITISH RCT. 1252 patients with NICM scar and ef<35%. ICD Vs no ICD. All cause mortality. Over 550 patients recruited. Australian sites opening in March. @TheBHF @SouthamptonCTU @ncurzen @josephselvanay2
1
3
12
11,380
Chris Agyingi, MD retweeted
What a line-up coming at #ACC26 in New Orleans. Not much antithrombotic science (pity), but a lot of interventional cardiology (good). Trials I’m most interested about: - CHAMPION-AF – LAA closure vs oral anticoagulation in AF. Another outcomes trial that may finally settle a long-standing debate. - STEMI-DTU – LV unloading before reperfusion in anterior STEMI without shock. Can physiology beat time-to-wire? - CHIP-BCIS3 – High-risk PCI with planned LV support vs standard care. Protection or overengineering? - ALL-RISE – Angio-derived physiology vs pressure wire to guide PCI. If positive, this could change cath lab workflows. - ORBITA-CTO – Sham-controlled CTO PCI. Symptom relief or placebo? Courageous and necessary. - SURVIV – Redo surgery vs transcatheter valve-in-valve for failed mitral bioprostheses. Real-world decision, real endpoints. - PRO-TAVI – TAVI without routine PCI. How minimalist can we safely be? - OPTIMA – IVUS-guided vs angiography-guided PCI in unprotected left main. Imaging vs eyeballing, once again, with outcomes. accscientificsession.acc.org…
4
36
1
106
10,062
Chris Agyingi, MD retweeted
The countdown has begun … in just over 2 weeks, @divaka_perera will present the results of @CHIP_BCIS3 on behalf of the trial group @BCIS_uk at #ACC2026 @ACCinTouch! The first RCT of elective unloading with a percutaneous LVAD v SOC in high-risk PCI. doi.org/10.1161/CIRCINTERVEN…
1
16
1
31
3,110
Chris Agyingi, MD retweeted
Fluid restriction in patients with heart failure: a systematic review heart.bmj.com/content/early/…
4
162
19
449
191,050
Chris Agyingi, MD retweeted
New era. New sound 🔊
583
4,100
1,686
34,450
1,733,289
Chris Agyingi, MD retweeted
Thrilled to announce the launch of the @CardioNerds Advanced Therapies Series! An honor to have @MKIttlesonMD as our inaugural guest-she shared incredible insights on timely advanced therapies referral & the acute management of heart failure. Check it out!
2
11
1,079
Chris Agyingi, MD retweeted
No trial better explains the importance of evidence than REVIVED BCIS. It boggles my mind that it was negative @divaka_perera is correct, but try telling 99% of American cardiologists We still cath new LV dys pts TO FIND LESIONS TO REVASC despite negative trials #ESC2025
Replying to @divaka_perera
@divaka_perera makes a strong case: routine #PCI should not be performed in asymptomatic pts with LV dysfunction (even with viability). It does NOT improve prognosis ‼️ Evidence should guide practice: The earth is not flat 🌎 #ESCCongress @escardio @drjohnm
29
53
3
245
47,035
*Register Today!* The Cardiogenic Shock Working Group 2025 Global Summit is officially happening Wed, June 4, 2025. *A FREE cvent.me/7gaeDW?sms=2 ##CSWG25 #CardiogenicShock
2
117
Chris Agyingi, MD retweeted
🚑 Shock Talk Just Got Real! 🎧 418. @CardioNerds x @CSWorkingGroup: LV Unloading in AMI Shock @Gurleen_Kaur96 @goodmra1 @NavinKapur4, @ShashankSinhaMD @rachkataria break down updated AMI shock guidelines & the Class 2A role of transvalvular flow pumps cardionerds.com/418-cardione…
3
22
56
5,481
🏥 You're seeing a new patient with fevers, tachycardia, a new murmur. Not a Janeway lesion or splinter hemorrhage in sight... ✋🩸 ...Now what? 🙀 Time for a #Tweetorial on the role of Multimodality #CardiacImaging in #InfectiveEndocarditis (via 2023 ESC Guidelines) 🧵
1
10
1
27
4,298
Chris Agyingi, MD retweeted
euuuuuuuuu
146
8,370
575
59,608
1,535,907
Chris Agyingi, MD retweeted
Sacubitril/Valsartan in patients with HF & deterioration in eGFR to <30 with therapy. Continuation of ARNi was associated with persistent clinical benefit and no incremental risk. @JACCJournals #JACCHF jacc.org/doi/10.1016/j.jchf.…
2
107
2
294
36,025
Chris Agyingi, MD retweeted
Brief 🧵on what to do when you lose the 'flash' when placing a central line. Here we see the resident getting into the vein and seeing the satisfying 'flash' of blood that we're looking for. But as we all know, things don't always go smoothly from there... (1 )
21
87
11
448
304,094